Nintedanib esylate

Founded in 2014, Shijiazhuang Dingmin Pharmaceutical Sciences distributes and manufactures a very extensive catalog of specialty active pharmaceutical ingredients and intermediates, spanning oncology (cabozantinib malate, ivosidenib, binimetinib, selumetinib sulfate, avatrombopag maleate), CNS and metabolic therapeutics (rimegepant, rimegepant sulfate, ozanimod hydrochloride, ivacaftor), and cardiovascular compounds (bevantolol hydrochloride), alongside chiral intermediates and specialized reagents. Offering CMO contract manufacturing with own-brand R&D capacity and requiring T/T payment before shipment, the company serves customers across Europe, Asia, the Middle East, Africa, and the Americas.